Hyloris Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Hyloris Pharmaceuticals's earnings have been declining at an average annual rate of -18.4%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 48.3% per year.
Key information
-18.4%
Earnings growth rate
3.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 48.3% |
| Return on equity | -40.6% |
| Net Margin | -560.1% |
| Next Earnings Update | 05 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Hyloris Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3 | -16 | 6 | 15 |
| 30 Sep 23 | 2 | -15 | 5 | 14 |
| 30 Jun 23 | 3 | -12 | 5 | 12 |
| 31 Mar 23 | 3 | -12 | 4 | 11 |
| 31 Dec 22 | 2 | -12 | 4 | 10 |
| 30 Sep 22 | 3 | -10 | 3 | 9 |
| 30 Jun 22 | 3 | -8 | 3 | 8 |
| 31 Mar 22 | 3 | -10 | 3 | 7 |
| 31 Dec 21 | 3 | -12 | 3 | 5 |
| 30 Sep 21 | 2 | -12 | 2 | 4 |
| 30 Jun 21 | 1 | -12 | 1 | 3 |
| 31 Mar 21 | 1 | -10 | 2 | 3 |
| 31 Dec 20 | 0 | -7 | 2 | 3 |
| 30 Sep 20 | 0 | -8 | 3 | 2 |
| 30 Jun 20 | 0 | -8 | 3 | 2 |
| 31 Mar 20 | 0 | -6 | 1 | 2 |
| 31 Dec 19 | 0 | -5 | 1 | 1 |
| 31 Dec 18 | 0 | -6 | 1 | 5 |
| 31 Dec 17 | 0 | -4 | 2 | 2 |
Quality Earnings: 52U is currently unprofitable.
Growing Profit Margin: 52U is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 52U is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.
Accelerating Growth: Unable to compare 52U's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 52U is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3%).
Return on Equity
High ROE: 52U has a negative Return on Equity (-40.6%), as it is currently unprofitable.